MDK and acute myeloid leukemia: Although AML has an extremely low mutational burden19, the overall enrichment of plasma B cells and cross-presenting dendritic cells in tumors may suggest tumor-specific antigen presentation in tumor microenvironment that may include all the genes/proteins highly expressed in AML, including CTSK and MDK.